Direct Oral Penicillin Challenge Noninferior to Standard of Care
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, July 25, 2023 -- For patients with low-risk penicillin allergy, direct oral penicillin challenge is noninferior to standard-of-care skin testing followed by oral challenge, according to a study published online July 17 in JAMA Internal Medicine.
Ana Maria Copaescu, M.D., from the Centre for Antibiotic Allergy and Research at Austin Health in Heidelberg, Australia, and colleagues examined whether a direct oral penicillin challenge is noninferior to the standard-of-care penicillin skin testing followed by oral challenge in an international randomized clinical trial. A total of 377 patients with a low-risk penicillin allergy were randomly assigned to direct oral challenge with penicillin (intervention arm; 187 patients) or standard-of-care penicillin skin testing (190 patients).
Most of the patients had a PEN-FAST score of 0 or 1. The researchers found that the primary outcome of physician-verified positive immune-mediated oral penicillin challenge within one-hour postintervention occurred in 0.5 and 0.5 percent of patients in the intervention and control groups, respectively, with a risk difference of 0.0084 percentage points (90 percent confidence interval, −1.22 to 1.24 percentage points). The one-sided 95 percent confidence interval was below the noninferiority margin of 5 percentage points. Nine immune-mediated adverse events were recorded in the intervention group and 10 were recorded in the control group in the five days following the oral penicillin challenge (risk difference, −0.45 percentage points; 95 percent confidence interval, −4.87 to 3.96 percentage points). There were no serious adverse events reported.
"Compared with skin testing, a direct oral penicillin challenge is less resource and time intensive, is less expensive, and has the potential to be performed outside of the specialist allergy setting, providing a scalable approach to address low-risk, unverified penicillin allergy in diverse treatment settings internationally," the authors write.
Two authors disclosed ties to the biopharmaceutical and medical technology industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Peanut Consumption Starting in Infancy Provides Lasting Tolerance
THURSDAY, May 30, 2024 -- Peanut consumption starting in infancy and continuing to age 5 years provides lasting tolerance into adolescence, according to a study published in the...
Recommendations Developed to Prepare Patients for Oral Immunotherapy
FRIDAY, April 19, 2024 -- In a research article published online April 8 in the Journal of Allergy and Clinical Immunology, consensus recommendations are presented for preparing...
Penicillin Allergy Can Be Delabeled by Nonallergy Providers
TUESDAY, April 9, 2024 -- Direct oral penicillin challenges (DPCs) can be delivered to patients with penicillin allergy labels (PALs) by nonallergy health care professionals...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.